Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Advantest | Eaton | Pfizer | |
|---|---|---|---|
| Moat rating | wide A disclosed share that rose while margin expanded. The FY2025 Annual Securities Report and Business Report (84th term, filed 2026-06-26) lists as FY2025 progress: 'Further expanded our market share in the semiconductor tester (ATE) market (CY2024: 58%; CY2025: 65%)', earned on net sales of ¥1,128,610 million at an operating income to net sales ratio of 44.2%, 'an increase of 14.9 percentage points from the previous fiscal year'. The share is a company metric and the filing says so — 'the ratio of Advantest's semiconductor tester sales to the overall size of the semiconductor tester market', where 'The semiconductor tester market size is estimated independently by Advantest based on certain assumptions and available information'. The same filing names seven principal tester competitors (Teradyne, Inc., CCTech, Accotest, YC Corp., Cohu, Inc., UniTest Co., Ltd. and EXICON Ltd.), so this is a lead held against a named field rather than an empty one. | wide The FY2025 10-K asserts a durable competitive position across essentially all of the revenue base: for Electrical Americas and Electrical Global it states 'Eaton has a strong competitive position in these segments and, with respect to many products, is considered among the market leaders'; it repeats that language verbatim for Aerospace ('industry-leading portfolio', 'considered among the market leaders'); and for Vehicle it states 'Eaton is considered among the market leaders in this segment.' That is a claimed leadership position in four of the five reported segments, on a base of $27.4 billion of 2025 revenue, ~97,000 employees and customers in 180 countries, from a company founded in 1911. The rating is tempered rather than lifted higher by the filing's own admissions - price is named among the principal methods of competition in the Electrical, Vehicle and eMobility segments, and the risk factors flag 'newly competitive market players' and that 'our positions may also be impacted by new entrants into our product or regional markets.' | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip What management itself names as the source of the position is a proprietary platform. The July 29, 2026 Q1 FY2026 results briefing states: 'Our leading SoC Test platform, V93000, has been widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets, where advanced packaging technologies including GPUs, ASICs, and CPUs are being adopted. It serves as a key foundation that underpins our competitive advantage.' The 84th-term report shows the spend behind it: R&D was approximately ¥71.4 billion in FY2024 and ¥78.1 billion in FY2025, 'The number of employees in its research and development division is approximately 30% of the Advantest workforce', and in the Test System Business Segment 'a large and ongoing investment in research and development is necessary in order to maintain market competitiveness'. Its stated IP mitigation is that 'Advantest strategically and proactively files patent applications during product development and prior to product shipment'. | switching costs The filing's own description of how it competes points at designed-in and qualified positions rather than IP or pure scale. In Aerospace the principal methods of competition are listed as 'total cost of ownership, product and system performance, quality, design engineering capabilities, and timely delivery' - price is conspicuously absent, and 20% of segment sales go to three large aircraft OEMs, i.e. platform-level content that is qualified in and hard to displace mid-programme. In the Electrical segments 'customer service and support' sits alongside performance and technology as a method of competition, and 22% of sales go to six large customers. Intangibles_ip is explicitly ruled out as the primary source by the company itself: 'management believes that the loss or expiration of any single intellectual property right would not in and of itself have a material effect on Eaton's consolidated financial statements or its business segments.' Scale is real but secondary - the filing notes raw materials are bought 'from many suppliers' and 'under normal circumstances, the Company has no difficulty obtaining its raw materials,' which reads as supply resilience rather than a cost advantage claim. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | clear leader The 84th-term report discloses Advantest's tester-market share at 65% in CY2025, up from 58% in CY2024, and carries the same 65% among its disclosed management metrics against a target of '58% or more'; the filing defines it as Advantest's semiconductor tester sales over a market size 'estimated independently by Advantest based on certain assumptions and available information'. The July 29, 2026 briefing names the platform behind that share — V93000, 'widely adopted across a broad range of customers in the increasingly complex AI semiconductor markets'. Teradyne, Inc. heads the filing's list of principal tester competitors. | co leader The filing's leadership language is plural and hedged, not exclusive: 'considered among the market leaders' for the Electrical segments (qualified further by 'with respect to many products'), 'among the market leaders' for Aerospace, and 'Eaton is considered among the market leaders' for Vehicle. Nowhere does the 10-K claim to be the single leader in any market, and it never names a competitor or cites a market-share figure. 'Among the market leaders' maps to co_leader, not clear_leader. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | strong Q1 FY2026 gross profit was ¥255,553 million on net sales of ¥367,473 million, and the July 29, 2026 briefing states the resulting figure itself: 'Gross margin reached 69.5%', with 'an operating margin of 51.7%'. Management attributes that level to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment', not to price, and guides FY2026 full-year gross margin to 66–67% and operating margin to 49.4% after incorporating 'the impact of higher component costs, particularly for memory-related components'. FY2025 closed at a 44.2% operating margin, up 14.9 points year on year, on sales up 44.7%. | moderate The filing describes pass-through ability that is real but bounded. On input costs: 'While we strive to recoup these increased costs through our pricing, product modifications or other mediating responses, if we are unable to do so without compromising the competitive position of our products and services, our results could continue to be impacted by this trend.' On macro conditions: 'our responses to mitigate the impact of these conditions, such as potential price increases, could negatively impact our market share or relationships with distributors or customers.' On tariffs: 'potential price increases or other mitigating efforts could negatively impact market share or otherwise increase the risk of customer disputes.' Price is also listed as a principal method of competition in Electrical Americas, Electrical Global, Vehicle and eMobility - so raising price is described by the company as costing share. Aerospace is the exception, where price is not among the listed methods of competition. The filing states no gross-margin trend in Item 1 or Item 1A. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Advantest sells the test step that certifies silicon before it ships, and its position there is disclosed rather than inferred: its own tester-market-share metric moved from 58% in CY2024 to 65% in CY2025 (84th-term Annual Securities Report), against a market size the filing says Advantest estimates itself. The lead is concentrated in SoC test — the July 29, 2026 briefing calls V93000 'our leading SoC Test platform' and 'a key foundation that underpins our competitive advantage' — and the customer base runs straight into the AI chain: NVIDIA International, Inc. was ¥228,273 million, or 20.2%, of FY2025 consolidated net sales, having been below the filing's 10% disclosure threshold the prior year, with Taiwan Semiconductor Manufacturing Co., Ltd. at ¥124,922 million, or 11.1%. Economics moved with it: FY2025 operating margin was 44.2%, up 14.9 points, and Q1 FY2026 gross margin reached 69.5%, which management attributes to 'a favorable sales mix and limited inventory valuation losses amid the robust demand environment' rather than to price. The counterweights sit in the same documents. The 84th-term report's customer-trust risk factor warns that if Advantest fails to meet expectations on ramp-up and post-sales service, 'the maintenance or expansion of Advantest's market share may be constrained'; it names separate competitor sets in test handlers (Hon. Precision, CCTech, Cohu, TechWing) and device interfaces (TSE, ISC, BeLINK) where no share is disclosed at all; and the July 29, 2026 briefing guides FY2026 full-year gross margin down to 66–67% having 'incorporated the impact of higher component costs, particularly for memory-related components, mainly in the second half of the fiscal year'. | Eaton describes itself in the FY2025 10-K as an 'intelligent power management company' making products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets, capitalising on 'the megatrends of the electrification, digitalization, and the reindustrialization of and growth of megaprojects in North America.' Its defensibility rests on positions the filing says are already at or near the front of their markets - a 'strong competitive position' in both Electrical segments and Aerospace, competed on performance, technology, service and, in Aerospace, engineering and total cost of ownership rather than price - reinforced by acquisitions aimed at owning more of the electrical value chain into the data center (Fibrebond for 'modular solutions for multi-tenant and hyperscale data center customers,' Resilient Power Systems to accelerate 'commercialization of solid-state transformer technology,' and an agreed acquisition of Boyd Thermal adding 'critical liquid cooling technology, enabling the Company to serve hyperscale and colocation customers from the chip to the grid'). The counterweight, stated by the company, is customer concentration and a portfolio in flux: on January 26, 2026 Eaton announced its intention to spin off its Mobility business (the legacy Vehicle and eMobility segments) into an independent public company, and re-segmented accordingly in Q1 2026. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Back-end capital equipment: Advantest's testers certify devices after fabrication, and the 84th-term report's FY2025 major-customer table puts NVIDIA International, Inc. at 20.2% and Taiwan Semiconductor Manufacturing Co., Ltd. at 11.1% of consolidated net sales, with overseas sales 97.8% of the total. | Upstream electrical infrastructure into AI compute: Eaton supplies the power path from grid to rack, and the 10-K makes that link itself - data center is the first market it names, it cites 'momentum in the data center and utility end markets,' and its 2025-26 acquisitions target hyperscale/colocation modular buildings, solid-state transformers and liquid cooling 'from the chip to the grid.' Its exposure to AI is as a supplier to AI buildout, not as an AI technology vendor; the filing's only AI discussion of its own products is a risk factor about keeping pace with AI internally and about generative-AI compliance risk, which is incidental to the thesis. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.42 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |